Abstract
The Congenital Disorders of Glycosylation (CDG) are a collection of over 20 inherited diseases that impair protein N-glycosylation. The clinical appearance of CDG patients is quite diverse making it difficult for physicians to recognize them. A simple blood test of transferrin glycosylation status signals a glycosylation abnormality, but not the specific defect. An abnormal trasferrin glycosylation pattern suggests that the defect is in either genes that synthesize and add the precursor glycan (Glc3Man9GlcNAc2) to proteins (Type I) or genes that process the protein-bound N-glycans (Type II). Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans. These types are expected to be mutually exclusive, but a group of patients is now emerging who have variable coagulopathy and hypoglycemia together with a combination of Type I and Type II transferrin features. This surprising finding makes identifying their defects more challenging, but the defects and associated clinical manifestations of these patients suggest that the N-glycosylation pathway has some secrets left to share.
Keywords: serum transferrin, carbohydrate deficient glycoprotein syndrome, MALDI-TOF-MS, LLO species, Electrospray Ionization Mass Spectrometry
Current Molecular Medicine
Title: Congenital Disorders of Glycosylation: CDG-I, CDG-II, and Beyond
Volume: 7 Issue: 4
Author(s): Hudson H. Freeze
Affiliation:
Keywords: serum transferrin, carbohydrate deficient glycoprotein syndrome, MALDI-TOF-MS, LLO species, Electrospray Ionization Mass Spectrometry
Abstract: The Congenital Disorders of Glycosylation (CDG) are a collection of over 20 inherited diseases that impair protein N-glycosylation. The clinical appearance of CDG patients is quite diverse making it difficult for physicians to recognize them. A simple blood test of transferrin glycosylation status signals a glycosylation abnormality, but not the specific defect. An abnormal trasferrin glycosylation pattern suggests that the defect is in either genes that synthesize and add the precursor glycan (Glc3Man9GlcNAc2) to proteins (Type I) or genes that process the protein-bound N-glycans (Type II). Type I defects create unoccupied glycosylation sites, while Type II defects give fully occupied sites with abnormally processed glycans. These types are expected to be mutually exclusive, but a group of patients is now emerging who have variable coagulopathy and hypoglycemia together with a combination of Type I and Type II transferrin features. This surprising finding makes identifying their defects more challenging, but the defects and associated clinical manifestations of these patients suggest that the N-glycosylation pathway has some secrets left to share.
Export Options
About this article
Cite this article as:
Freeze H. Hudson, Congenital Disorders of Glycosylation: CDG-I, CDG-II, and Beyond, Current Molecular Medicine 2007; 7 (4) . https://dx.doi.org/10.2174/156652407780831548
DOI https://dx.doi.org/10.2174/156652407780831548 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Is High Oral Dose L-arginine Intake Effective in Leukoaraiosis? Preliminary Data, Study Protocol and Expert’s Opinion
Current Aging Science Natural Steroids and Androgen Antagonists used as Neuroprotection in Common Neurological Disorders
CNS & Neurological Disorders - Drug Targets Anti-Inflammatory Approaches that Target the Chemokine Network
Recent Patents on Inflammation & Allergy Drug Discovery Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders An Expanded, Unified Substrate Recognition Site Map for Mammalian Cytochrome P450s: Analysis of Molecular Interactions Between 15 Mammalian CYP450 Isoforms and 868 Substrates
Current Drug Metabolism The Caveolin-1 Connection to Cell Death and Survival
Current Molecular Medicine Meet Our Editorial Board Member
Current Cancer Drug Targets Interferon-Beta Therapy Monitoring in Multiple Sclerosis Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Synthesis and Biological Evaluation of Scutellaria Flavone Cyclaneaminol Mannich Base Derivatives as Novel CDK1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Hyperhomocysteinemia and Sudden Cardiac Death: Potential Arrhythmogenic Mechanisms
Current Vascular Pharmacology The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Phosphodiesterase 3 (PDE3): Structure, Localization and Function
Cardiovascular & Hematological Agents in Medicinal Chemistry Emerging Role and Targeting of Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CEACAM6) in Human Malignancies
Clinical Cancer Drugs Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry Dietary Intake in HIV-Infected Men with Lipodystrophy: Relationships with Body Composition, Visceral Fat, Lipid, Glucose and Adipokine Metabolism
Current HIV Research Mechanisms for Progenitor Cell-Mediated Repair for Ischemic Heart Injury
Current Stem Cell Research & Therapy The Nutrigenetics and Pharmacogenetics of Vitamin D Pathways
Current Pharmacogenomics and Personalized Medicine Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Meet Our Editorial Board Member:
Current Aging Science Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design